絞り込み

16404

広告

「elotuzumab」の検索結果

159件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

[Multiple myeloma : What has been confirmed in therapy?]

A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.

SLAMF7-CAR T-cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes.

Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice.

Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Treatment algorithms for multiple myeloma in Japan.

Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma.

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Adoptive Cell Therapy in Multiple Myeloma.

The Clinical Pharmacology of Elotuzumab.

Immunotherapy in Multiple Myeloma.

How I treat: New agents in myeloma.

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.

Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).

How I treat first relapse of myeloma.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
Sort by
※並べ替えは表示に時間がかかります